RxDoctor Payments Data

Vaibhav Verma, MD

Hematology & Oncology · Canfield, OHNPI 1689806705

Payments from drug & device makers

$15,143in general payments, 2019–2025

Across 705 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$868
  • Merck$836
  • Pfizer$662
  • E.r. Squibb & Sons, L.L.C.$587
  • AbbVie$579
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$14,72897%
  • Education$4143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis54$1,028
AstraZeneca(2 entities)40$868
Merck34$836
Pfizer41$662
E.r. Squibb & Sons, L.L.C.24$587
AbbVie28$579
Bristol Myers Squibb33$556
Takeda Pharmaceuticals U.S.A., Inc.18$553
Eisai Inc.24$538
Johnson & Johnson25$531
GSK21$466
Genentech USA, Inc.26$460
Amgen18$421
Astellas Pharma US Inc16$393
Sanofi19$390
Lilly USA, LLC16$374
Daiichi Sankyo Inc.19$342
Regeneron Healthcare Solutions, Inc.11$336
Pharmacyclics LLC, An Abbvie Company14$321
Blueprint Medicines Corporation6$298
Dendreon Pharmaceuticals LLC8$216
EMD Serono, Inc.8$193
Gilead(2 entities)9$186
Exelixis Inc.4$184
AVEO Pharmaceuticals, Inc.9$183
Incyte Corporation11$175
Syndax Pharmaceuticals, Inc.2$142
Genmab U.S., Inc.6$136
Immunogen, Inc.1$130
Acrotech Biopharma Inc.6$130
Stemline Therapeutics Inc.6$125
Pharmacosmos Therapeutics Inc.6$120
Boehringer Ingelheim7$112
Bayer6$105
Sobi, Inc6$105
Agios Pharmaceuticals, Inc.4$105
Jazz Pharmaceuticals Inc.5$103
Ipsen Biopharmaceuticals, Inc5$103
Octapharma USA, Inc.5$102
Seagen Inc.6$97
Taiho Oncology, Inc.5$93
Karyopharm Therapeutics Inc.5$85
Puma Biotechnology, Inc.5$80
Sumitomo Pharma America, Inc.2$76
ADC Therapeutics America, Inc.4$72
Myriad Genetic Laboratories, Inc.3$70
Kyowa Kirin, Inc.4$68
Rigel Pharmaceuticals, Inc.5$67
Servier Pharmaceuticals LLC3$67
Sanofi US Services Inc.1$65
Beigene USA, Inc.3$64
Tempus AI, Inc3$60
Sun Pharmaceutical Industries Inc.3$59
Array Biopharma Inc4$58
Novo Nordisk1$57
Caris MPI, Inc.3$57
Tersera Therapeutics LLC3$55
Biocon Biologics Inc2$46
Apellis Pharmaceuticals, Inc.3$45
Beone Medicines USA, Inc.2$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,143 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,382,955
Medicare patients
336
Services billed
59,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate23$401,826
SprycelDasatinib16$287,099
LibtayoCemiplimab-Rwlc18$187,431
Neulasta OnproPegfilgrastim27$164,118
Darzalex FasproDaratumumab-Hyaluronidase-Fihj15$143,023
ZirabevBevacizumab-Bvzr26$104,819
XgevaDenosumab25$80,496
Azacitidine20$68,949
VenclextaVenetoclax17$67,784
EliquisApixaban85$63,318
XareltoRivaroxaban17$12,507
AranespDarbepoetin Alfa In Polysorbat20$6,896
Bortezomib27$5,908
Enoxaparin Sodium12$2,093
Hydroxyurea17$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$1,028$401,82623 claims
E.r. Squibb & Sons, L.L.C.Sprycel$587$287,09916 claims
Regeneron Healthcare Solutions, Inc.Libtayo$336$187,43118 claims
PfizerZirabev, Eliquis$662$168,137111 claims
AmgenXgeva, Aranesp$421$87,39245 claims
AbbVieVenclexta$579$67,78417 claims
Johnson & JohnsonXarelto$531$12,50717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Canfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →